Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Company profile
Ticker
ARVN
Exchange
Website
CEO
John G. Houston
Employees
Incorporated
Location
Fiscal year end
Former names
Arvinas, Inc.
SEC CIK
IRS number
463139663
Latest filings (excl ownership)
Latest ownership filings
News
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87
15 Apr 24
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $87
12 Apr 24
Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
11 Apr 24
Truist Securities Reiterates Buy on Arvinas, Maintains $65 Price Target
25 Mar 24
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
1 Mar 24
Press releases
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
24 Apr 24
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 Apr 24
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
18 Mar 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Feb 24